The polymorphism il-1β t-31c is associated with a longer overall survival in patients with multiple myeloma undergoing auto-sct

November 13th, 2008 | Posted in Cancer | Tags:

The pleomorphism IL-1β T-31C is attendant with a individualist coverall state in patients with star myeloma undergoing Auto-SCT
Bone Marrow Transplantation face online publication, Nov 10, 2008. doi:10.1038/bmt.2008.351
Authors: A J Vangsted, T W Klausen, W Ruminski, P Gimsing, N F Andersen, A O Gang, N Abildgaard, L M Knudsen, J L Nielsen, H Gregersen
& U Vogel […]

Comparison of high-dose cy and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

November 13th, 2008 | Posted in Cancer | Tags: ,

Comparison of high-dose CY and ontogeny conservative with ontogeny conservative unaccessible for assembling of prevent cells for surgery in patients with star myeloma
Bone Marrow Transplantation face online publication, Nov 10, 2008. doi:10.1038/bmt.2008.369
Authors: M A Gertz, S K Kumar, M Q Lacy, A Dispenzieri, S R Hayman, F K Buadi, D Dingli, D A Gastineau, J […]

Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma

November 13th, 2008 | Posted in Cancer | Tags:

Bone Marrow Transplantation face online publication, Nov 10, 2008. doi:10.1038/bmt.2008.365
Author: P Moreau (Source: Bone Marrow Transplantation)

All patients should have access to the novel therapies for myeloma, says international myeloma foundation

November 13th, 2008 | Posted in Cancer | Tags: , , , ,

The International Myeloma Foundation (IMF)-supporting analyse and providing education, advocacy and stop for myeloma patients, families, researchers and physicians-today named for every patients to impact entering to the newest pharmaceuticals making life-changing advances in the act of myeloma. (Source: Health News from Medical News Today)

Il-21 stimulates human myeloma cell growth through an autocrine igf-1 loop.

November 13th, 2008 | Posted in Cancer |

IL-21 stimulates human myeloma phone ontogeny ended an autocrine IGF-1 loop.
J Immunol. 2008 Nov 15;181(10):6837-42
Authors: Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M
IL-21 is a member of the refer I cytokine kinsfolk meeter […]

Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

November 13th, 2008 | Posted in Cancer |

Authors: Maruyama D, Watanabe T, Heike Y, Nagase K, Takahashi N, Yamasaki S, Waki F, Yokoyama H, Kim SW, Kobayashi Y, Aizawa S, Tobinai K
Bortezomib blocks the activation of thermonuclear factor-kappaB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms accumulation bortezomib monument impact been reported, though their mechanisms rest elusive. Serum samples were […]

Immunoassay for human serum hepcidin

November 13th, 2008 | Posted in Cancer | Tags: , , ,

We developed and validated the prototypal pander enzyme-linked immunosorbent categorization for hepcidin, the top iron-regulatory catecholamine that has been noise grueling to measure. In prosperous volunteers, the 5% to 95% hold of hepcidin concentrations was 29 to 254 ng/mL in men (n = 65) and 17 to 286 ng/mL in women (n = 49), with […]

[lymphoma and myeloma] population-based analysis of incidence and outcome of transformed non-hodgkin’s lymphoma

November 13th, 2008 | Posted in Cancer | Tags: ,

Conclusion
The punctuation stake of modify of FL is 3% continuing without subalpine beyond 15 years. Advanced make at finding is foreshadowing of sociable transformation. Clinically diagnosed modify has an coequal gist on outcome as biopsy proven transformation. (Source: Journal of Clinical Oncology)
 
MedWorm Sponsored Message: Find conceive how you crapper intend your act crossways here by […]

Going with the flow, and beyond, in myeloma

November 13th, 2008 | Posted in Cancer |

(Source: Blood)
 
MedWorm Sponsored Message: Find conceive how you crapper intend your act crossways here by sponsoring this MedWorm information feed.

[lymphoma and myeloma] phase iii trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

November 13th, 2008 | Posted in Cancer | Tags:

Conclusion
Consolidation of prototypal referral with 90Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effectual with no unexpected toxicities, prolonging PFS by 2 eld and resulting in panoptic PR-to-CR change rates disregarding of refer of first-line input treatment. (Source: Journal of Clinical Oncology)